NasdaqGS:EWTXPharmaceuticals
A Look At Edgewise Therapeutics (EWTX) Valuation After Encouraging Long Term Sevasemten Becker Data
Edgewise Therapeutics (EWTX) put fresh clinical data in front of investors after presenting updated long term results from its MESA open label extension study of sevasemten in Becker muscular dystrophy.
See our latest analysis for Edgewise Therapeutics.
At a share price of US$29.94, Edgewise Therapeutics has seen a 26.76% 90 day share price return and a 297.61% three year total shareholder return. This suggests momentum has built as sevasemten data and recent conference appearances keep...